Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-10-04 am EDT
9958.00 GBX   +1.55%
07:38aAlexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine
AQ
04:19aSwitzerland's Roche Secures US FDA Nod for Breast Cancer Drug Enhertu's Companion Diagnostic
MT
10/03AstraZeneca Unit To Buy US Biotech LogicBio Therapeutics
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FTSE 100 ends higher as AstraZeneca offsets commodity losses

08/15/2022 | 05:39am EDT

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window)

* AstraZeneca jumps on positive cancer drug update

* Focus on UK labour, CPI data later this week

* FTSE 100 up 0.1%, FTSE 250 adds 0.2%

Aug 15 (Reuters) - Britain's blue-chip share index ended higher on Monday, as gains in drugmaker AstraZeneca and consumer stocks relieved pressure from losses in mining and oil heavyweights after data showed China's economy unexpectedly slowed last month.

The FTSE 100 rose 0.1% to hold near 10-week highs, while the midcap FTSE 250 index climbed 0.2%.

The mood was sombre across global stock markets, with investors turning to defensive sectors such as healthcare and consumer staples amid worries about the health of the world's second-largest economy.

"People are going to be worried a whole lot over the global economy," said Capital Economics' Oliver Allen.

"So if you're looking at things through that kind of risk premia, that's a bit worse for energy, materials, financials and some of the things that the FTSE 100 specialises in."

The FTSE 100 has outperformed its global peers this year due to its large exposure to commodity stocks that have surged on the back of a jump in oil and metal prices. A weakening pound has also boosted dollar earners in the index.

The FTSE 100 is up nearly 2% so far this year, while the MSCI world equities index has shed almost 13%.

Oil major Shell and miners Rio Tinto and Anglo American slipped on Monday, in tandem with weaker commodity prices, after data from China data raised fears about weakening demand.

Investors are awaiting the British employment report as well as consumer prices data later this week to gauge the state of the labour market and inflation.

The data could offer clues on whether the Bank of England opts for a second consecutive 50 basis points rate hike at its September meeting.

AstraZeneca gained 2.3% after the drugmaker said its cancer drug, Enhertu, developed with Japan's Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients. (Reporting by Sruthi Shankar and Aniruddha Ghosh in Bengaluru; editing by Uttaresh.V, Vinay Dwivedi and Alex Richardson)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.55% 9958 Delayed Quote.13.00%
DAIICHI SANKYO CO., LTD. 3.19% 4237 Delayed Quote.40.38%
FTSE 100 2.57% 7086.46 Delayed Quote.-6.44%
FTSE MID 250 INDEX 3.11% 17822.15 Delayed Quote.-26.39%
LONDON BRENT OIL 3.53% 91.75 Delayed Quote.12.85%
RIO TINTO PLC 3.02% 5089 Delayed Quote.0.98%
SHELL PLC 1.67% 2338 Delayed Quote.41.79%
WTI 3.78% 86.348 Delayed Quote.10.63%
All news about ASTRAZENECA PLC
07:38aAlexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth..
AQ
04:19aSwitzerland's Roche Secures US FDA Nod for Breast Cancer Drug Enhertu's Companion Diagn..
MT
10/03AstraZeneca Unit To Buy US Biotech LogicBio Therapeutics
MT
10/03Astrazeneca : Transparency Directive - Form 6-K
PU
10/03ADRs End Higher, ABB and AstraZeneca Trade Actively
DJ
10/03Sector Update: Health Care Stocks Mostly Higher in Afternoon Trading
MT
10/03AstraZeneca Unit to Acquire LogicBio Therapeutics; LogicBio Shares Soar
MT
10/03LogicBio Therapeutics Shares Soar on Takeover by AstraZeneca
DJ
10/03Southern District Of New York Dismisses Putative Class Action Against Pharmaceutical Co..
AQ
10/03Sector Update: Health Care Stocks Edge Higher Premarket Monday
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 378 M - -
Net income 2022 4 553 M - -
Net Debt 2022 24 544 M - -
P/E ratio 2022 39,5x
Yield 2022 2,67%
Capitalization 172 B 172 B -
EV / Sales 2022 4,42x
EV / Sales 2023 4,10x
Nbr of Employees 83 100
Free-Float 96,5%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 110,85 $
Average target price 141,86 $
Spread / Average Target 28,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.00%171 771
JOHNSON & JOHNSON-4.60%429 082
ELI LILLY AND COMPANY17.06%305 529
ROCHE HOLDING AG-15.04%267 122
PFIZER, INC.-25.25%247 729
ABBVIE INC.2.16%244 563